Keep add-on products out of automatic purchasing
Require a product-specific clinical and regulatory review before placing a new item on an approved purchasing list. Marketing terms such as “stack,” “recovery,” or “body composition” do not demonstrate safety, efficacy, or a lawful sourcing pathway. FDA identifies safety concerns for several commonly promoted peptides, including CJC-1295 and ipamorelin.
Specify the exact product, not an informal shorthand
A purchasing request should identify the active ingredient, formulation, concentration, package size, and intended route as approved by the clinician. Do not let a slash-separated product nickname stand in for a defined preparation. Treat any change in formulation or source as a new review.
Keep clinical and purchasing decisions separate
The medical director determines whether a treatment is appropriate; purchasing checks the approved specification, supplier evidence, order terms, and receiving records. Use the supplier evaluation checklist and 503A versus 503B guide to make the handoff explicit.
Use a documented replacement process
If an approved item is unavailable, escalate to the clinical lead rather than substituting another peptide or combination. Compare changes in packaging, concentration, storage, and documentation before approving a replacement source. Keep the old and new lot records distinguishable for traceability.